Xtx Topco LTD Nuvation Bio Inc. Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 132,029 shares of NUVB stock, worth $382,884. This represents 0.02% of its overall portfolio holdings.

Number of Shares

132,029

Holding current value

$382,884

% of portfolio

0.02%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.3 - $3.83 $303,666 - $505,671	132,029 New	132,029 $303,000
Q1 2024 May 13, 2024	SELL	$1.46 - $3.97 $101,835 - $276,907	-69,750 Reduced 28.56%	174,490 $635,000
Q4 2023 Feb 13, 2024	BUY	$0.96 - $1.53 $208,959 - $333,028	217,666 Added 819.09%	244,240 $368,000
Q3 2023 Nov 13, 2023	SELL	$1.26 - $2.1 $8,793 - $14,655	-6,979 Reduced 20.8%	26,574 $35,000
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $24,992 - $29,478	-16,021 Reduced 32.32%	33,553 $60,000
Q1 2023 May 12, 2023	SELL	$1.6 - $2.48 $524 - $813	-328 Reduced 0.66%	49,574 $82,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $83,835 - $124,755	49,902 New	49,902 $95,000
Q2 2022 Aug 15, 2022	BUY	$3.24 - $5.85 $182,434 - $329,395	56,307 New	56,307 $182,000

Others Institutions Holding NUVB

# of Institutions

159

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

Decheng Capital LLC Menlo Park, CA

26M
Shares

$75.3 Million
14.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

19.2M
Shares

$55.7 Million
1.92% of portfolio
Black Rock Inc. New York, NY

16.2M
Shares

$47.1 Million
0.0% of portfolio
Omega Fund Management, LLC Boston, MA

13.1M
Shares

$37.9 Million
44.61% of portfolio
Octagon Capital Advisors LP New York, NY

12.2M
Shares

$35.3 Million
6.76% of portfolio

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $630M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account